| Biomarker ID | 513 |
| PMID | 20068566 |
| Year | 2010 |
| Biomarker | CSPG2+ WNT10B+E2F3+CDKN2A+TYMS+TGFB3+ALOX12+CD44+LAF4 |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated with Biochemical Recurrence |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Biochemical recurrence Vs No recurrence |
| Type of Biomarker | Prognostic |
| Cohort | Total of 139 (GSE18655) patients were chosen for this study out of which 69 were fusion positive and 70 were fusion negative and 33 experienced biochemical recurrence. The cohort was combined with another Cohort (Minnesota : n=596) to find this common gene signature. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | Univariate: p=0.0000002; Multivariate: p=0.0270 |
| Method Used | cDNA mediated , annealing, selection, extension and litigation (DASL) |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on Independent Patient Dataset |
| Technical Name | NA |